Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12/13/2023 is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claims 1–1 8 are rejected under 35 U.S.C. § 112(b) (or pre ‑ AIA 35 U.S.C. § 112, second paragraph) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor regards as the invention. The claim s 1 and 16 recite s structural and geometric features “of the self ‑ expanding stent” without actually reciting the stent as a claimed element of the system. T he claims rely on characteristics of an unclaimed article to define the scope of the recited system, creating ambiguity as to what structure in the claimed system possesses the recited features and rendering the metes and bounds of the claims unclear. See MPEP § 2111.04 (limitations must be positively recited and not merely tethered to an unclaimed article), and MPEP § 2173.02 (claims must reasonably apprise those skilled in the art of their scope). To overcome this indefiniteness, the claims should be amended to positively recite the “self ‑ expanding stent” as a claimed element (e.g., “a self ‑ expanding stent having …”) or to recast the limitations so that the recited structural/geometry features are expressly attributes of the claimed system components (e.g., “a stent retention member configured with …”) rather than attributes of an unclaimed stent. In claim 2, the phrase “the first portion being formed closer to the proximal end of the self-expanding stent retention sleeve than the second portion” references position of a feature on the stent by comparison to the sleeve’s proximal end, not to the stent’s proximal end. This can be indefinite or confusing as to the reference frame. All remaining claims are rejected as being dependent from a rejected base claim. Allowable Subject Matter Claims 1-1 8 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), 2nd paragraph, set forth in this Office action. The prior art fail to disclose a stent delivery system comprising: a pushwire having a distal end with at least one groove formed therein; a self-expanding stent retention sleeve disposed coaxially about the pushwire, the sleeve having a proximal end, a distal end, and a central section with a plurality of slots defining a plurality of struts; and a self-expanding stent disposed within the stent retention sleeve and having a proximal end with at least one protrusion; wherein, when the stent retention sleeve is in a radially constrained configuration, the at least one protrusion of the self-expanding stent is received in the at least one groove of the pushwire to releasably couple the self-expanding stent to the pushwire; and wherein, when the stent retention sleeve transitions from the radially constrained configuration to an unconstrained configuration, the distal end of the stent retention sleeve moves toward the proximal end of the stent retention sleeve to disengage the at least one protrusion from the at least one groove and thereby deploy the self-expanding stent. US 9744035 B2 (“Everting Heart Valve”) does not read on (anticipate) the stent delivery system claims 1-16 . While it does disclose a tubular, expandable anchor that can foreshorten during deployment, its anchor is part of a heart valve replacement system and is actuated by control wires/tubes for active foreshortening. It does not teach the specific combination of features in claims — namely, a self ‑ expanding, slotted retention sleeve with continuous rings at both ends, fixed at its proximal ring to a pushwire, expanding only in its central section when unconstrained, and passively foreshortening to translate its distal ring proximally to release a stent. The Everting Heart Valve’s anchor is a different structure and operates in a different context. US-8157853-B2 does not teach or suggest: A self-expanding slotted sleeve with continuous end rings. Proximal ring fixed to pushwire. Central-only expansion and foreshortening-driven release. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT TAN-UYEN THI HO whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-4696 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Normal Schedule M-F Between 7:00 am and 4:00 pm . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT TAN-UYEN T HO can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 7034745263 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAN-UYEN T HO/ Supervisory Patent Examiner, Art Unit 3771